Open AccessTargeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells
Author(s) -
Shibin Zhou,
Phillip Buckhaults,
Leigh Zawel,
Fred Bunz,
Greg Riggins,
Jia Le Dai,
Scott E. Kern,
Kenneth W. Kinzler,
Bert Vogelstein
Publication year - 1998
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.95.5.2412
Subject(s) - transforming growth factor , acvrl1 , biology , carcinogenesis , cancer research , gene , colorectal cancer , suppressor , transforming growth factor beta , signal transduction , homologous recombination , genetics , tgf beta signaling pathway , activin type 2 receptors , mutation , homologous chromosome , cancer , microbiology and biotechnology , endoglin , cd34 , stem cell
Smad4 (DPC4 ) is a candidate tumor suppressor gene that has been hypothesized to be critical for transmitting signals from transforming growth factor (TGF) β and related ligands. To directly test this hypothesis, theSmad4 gene was deleted through homologous recombination in human colorectal cancer cells. This deletion abrogated signaling from TGF-β, as well as from the TGF-β family member activin. These results provide unequivocal evidence that mutational inactivation ofSmad4 causes TGF-β unresponsiveness and provide a basis for understanding the physiologic role of this gene in tumorigenesis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom